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106identify disease-modifying treatments. Although trials are designed to meet regulatory and registra-
tion requirements, many do not measure outcomes of the disease most relevant to key stakeholders.
Methods: A systematic review sought research that elicited information from people with AD, their
caregivers, and health-care professionals on which outcomes of the disease were important. Studies
published in any language between 2008 and 2017 were included.
Results: Participants in 34 studies described 32 outcomes of AD. These included clinical (memory,
mental health), practical (ability to undertake activities of daily living, access to health information),
and personal (desire for patient autonomy, maintenance of identity) outcomes of the disease.
Discussion: Evidence elicited directly from the peoplemost affected byAD reveals a range of disease
outcomes that are relevant to them but are not commonly captured in clinical trials of new treatments.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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2341. Background
Dementia has a substantial global impact, affecting over
46 million people in 2015 and costing an estimated US
$818 billion [1]. Alzheimer’s disease (AD) is the most com-
mon cause of dementia, accounting for 50-70% of cases
[2,3]. AD is typically characterized by impairments in
memory, executive functions, and activities of daily living
(ADLs), but the range and impact of symptoms and
outcomes across the disease spectrum are diverse. The
underlying causes of AD and effective treatments for the
disease remain elusive [3,4].
Clinical trials involving patients with AD continue to
try to identify disease-modifying treatments. However,
although such trials may meet regulatory and registration
requirements, they may not provide convincing evidence
of relevance to patients, caregivers, or health-care pro-
fessionals. Some trials are criticized for using inappro-
priate or inadequately sensitive endpoints [4,5], and it
is often unclear how much stakeholder input, other
than that of regulators, is applied in the selection of
trial endpoints [5].
Helping key stakeholders to understand which AD out-
comes are most relevant and what constitutes a meaning-
ful delay in disease progression could help researchers
develop and evaluate relevant, effective treatments and
improve health services and care [6]. This systematic re-
view, conducted on behalf of the international consortium
Real World Outcomes Across the AD Spectrum for Better
Care (ROADMAP; https://roadmap-alzheimer.org/),
aimed to collate all available evidence about prioritization
of AD outcomes and criteria for meaningful disease pro-
gression from the perspective of patients, caregivers, and
health-care professionals. ROADMAP partners will seek
to match these to “real-world evidence” sources,
including disease registries, population-based cohort
studies, and electronic health records documenting routine
patient care.
We sought evidence from studies covering a spectrum
from prodromal AD and mild cognitive impairment (MCI)
to confirmed AD dementia [7]. We sought research studies
that elicited information from stakeholders, addressing the
following research questions:
1. Which outcomes of AD across the spectrum are prior-
itized by patients, caregivers, and health-care profes-
sionals?
2. What do these stakeholders consider a meaningful
delay in progression of AD across the spectrum?235
236
237
238
239
240
241
2422. Methods
The systematic review protocol is available in the PROS-
PERO database (https://www.crd.york.ac.uk/PROSPERO/
display_record.php?RecordID575722).FLA 5.5.0 DTD  DADM307_proof 2.1. Search strategy
We developed a search strategy for the MEDLINE data-
base, balanced for sensitivity and specificity, and adapted
it for use in Embase, CINAHL, and PsycINFO (Table S1).
We developed groups of search terms for each research ques-
tion based on relevant ROADMAP reports [8,9]. We
combined terms related to AD across the disease spectrum,
stakeholder groups and study methods, with terms related
to outcomes and priority (for research question 1) and
separately with terms related to a meaningful delay of
disease (for research question 2). We combined all
searches to remove duplicates. We searched for gray
literature using “Alzheimer” in combination with
“outcome” or “progression”, applying date limits 2008-
2017 on relevant websites (Table S1).
We included relevant studies regardless of language by
arranging translation into English by colleagues. We sought
additional relevant studies through manual searches of key
articles’ citation lists and checking relevant conference ab-
stracts for full publications.2.2. Study screening, quality appraisal, and selection
We established specific inclusion and exclusion criteria to
guide the selection of relevant studies for inclusion and
screened the titles and abstracts of all retrieved citations
(Table 1). Two members of the research team independently
screened the first half of the retrieved citations, with 95%
agreement on decisions to include/exclude (Cohen’s kappa,
0.53 [0.42-0.64]). A discussion of discrepancies with a third
member of the team revealed that most disagreements were
due to the appraiser including potentially relevant articles
that did notmeet all inclusion criteria. The risk ofmissing rele-
vant evidence was considered to be low; hence, one research
team member screened the remaining half of the citations.
Two members of the team independently used published
tools with our inclusion and exclusion criteria to appraise the
full text of articles that passed screening for relevance and
quality. Checklists from the Clinical Appraisal Skills Pro-
gram were used to appraise qualitative studies (http://
www.casp-uk.net/casp-tools-checklists) and the National
Institute of Health for quantitative studies (https://www.
nhlbi.nih.gov/health-topics/
study-quality-assessment-tools). Discrepancies were dis-
cussed by the team and resolved through consensus.
Through iterative discussion, we established a minimum
quality threshold for inclusion, agreeing to exclude studies
with incomplete descriptions of recruitment or analysis or
unclear reporting of results which did not allow appraisal
of their rigor.2.3. Data extraction
For each included study, onemember of the research team
completed data extraction, noting the research approach,9 January 2019  11:35 pm  ce
243
Table 1
Inclusion and exclusion criteria
Included all relevant studies which elicited information from an included stakeholder group which answered one or both research questions from the
perspective of one (or more) of the following groups:
2patients with AD across the spectrum;
2people caring informally for individuals with AD across the spectrum, including, but not limited to, family
members, unpaid caregivers, and advocates;
2health-care professionals or clinicians looking after patients with AD across the spectrum, including, but not
limited to, neurologists, geriatricians, psychiatrists, family doctors, nurses, therapists, professions allied to
medicine, and formal, paid caregivers/support workers, where results could be differentiated from informal,
unpaid, or familial caregivers.
 used an appropriate and explicit research methodology to gather the required research data, including the use of
surveys, focus groups, or interviews to gather views directly from subjects
 met a minimum quality threshold
 were published between 2008 and 2017, inclusive
Excluded all relevant studies which  did not allow information related to AD across the spectrum to be distinguished from other conditions such as
stroke, multiple sclerosis, and epilepsy, or other causes of dementia and cognitive impairment, unless they
occurred as AD comorbidities
 only included information on patients with dementia or cognitive impairment caused by a condition other than
AD or dementia of an undefined or nonspecific etiology
 did not provide sufficient data to answer the research questions, such as commentaries, opinion pieces, or
conference abstracts
 failed to provide the required information (year of publication, title, abstract) for filtering when extracted from
the source
 reported on AD outcomes as measured by diagnostic tools or interventions without including the views of one of
our stakeholder groups on their importance.
Abbreviation: AD, Alzheimer’s disease.
C. Tochel et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring- (2018) 1-17 3
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graphics, disease stage, data analysis and synthesis methods,
research findings, and conclusions (Table S2). At least one
additional member of the team verified the extracted data.346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
3772.4. Data synthesis process
We extracted quotations and other study findings that
referred to outcomes or meaningful delay of AD across the
disease spectrum. We sought feedback from consortium col-
leagues to group specific outcomes into overarching do-
mains (e.g., memory within the cognition domain) (Table
2). Because many outcomes were multifaceted and some
overlapped domains, we placed each outcome where it fitted
best according to clinical nosology (e.g., grouping behav-
ioral, mental, and neuropsychiatric outcomes as used in in-
ternational classification systems [10]) and previous
ROADMAP activities [11].
To allow integration of evidence emerging from studies
using a range of different methodologies, we established a
framework for deciding which of the outcomes discussed
within each study should be considered important from the
perspective of the relevant stakeholder group. In studies
where outcomes were directly ranked for priority, the top
50% of outcomes were included. In studies where outcomes
were surveyed for importance but not ranked in the order of
priority, outcomes that were deemed important by over 50%
of participants were included. In studies adopting qualitative
methods, outcomes that were grouped into themes by au-
thors or that recurred frequently in participant quotations
were included.FLA 5.5.0 DTD  DADM307_proof 3. Results
Of the 3772 citations identified in the deduplicated
searches, we excluded 3653 at title/abstract screening and
a further 92 after full-text screening (Fig. 1). In addition to
the 27 studies that passed full-text review and quality
appraisal, we further found seven studies meeting all inclu-
sion criteria through citation searching key articles and
follow up of relevant conference abstracts. No additional
studies were found through the gray literature search.3.1. Study characteristics
The 34 included studies (representing 32 distinct research
projects) were conducted in 13 countries (Fig. 2). Individual
studies involved between four and 1116 participants. Twenty
studies recruited patients with MCI or AD dementia, 23 re-
cruited caregivers, and six recruited health-care profes-
sionals (the majority of whom were generalist or specialist
physicians and community or nursing home nurses; details
are shown in Table 3). No studies included the views of pa-
tients living with preclinical or prodromal AD or with AD at
the severe end of the spectrum.
Qualitative methods were used in 23 studies [12,14,16–
23,25,27,30–35,38,42–45], nine used quantitative methods
[13,24,26,29,36,37,39–41], and two used mixed methods
[15,28] (Table 3). Six studies included explicit prioritization
of outcomes through ranking or survey responses from
stakeholders [13,24,26,29,36,40]; the rest included relevant
material in the form of quotations and themes from
interviews or focus groups that was used to infer the9 January 2019  11:35 pm  ce
Table 2
Domains and outcomes: the number of included studies in which each outcome was considered important and the number of countries involved in those studies
Overarching domain Outcome Definition
No. of studies in which the
outcome was considered
important by:
The overall no. of studies
in which the outcome was
considered important
(range: 1-11)
No. of countries
represented in
relevant studies
(range: 1-10)Patients Caregivers HPs
Cognition Memory/slowing of forgetfulness Recalling names, events, and dates;
general forgetfulness; slowing of
memory loss
5 6 1 10 6
Language and communication Verbal and written communication, such
as verbal fluency and object naming
3 3 - 6 3
General cognitive health Cognitive functioning without explicitly
referring to a specific cognitive
function
1 1 1 2 2
Judgment and insight Ability to retain an intuitive
understanding of oneself and of the
disease process
2 1 - 2 1
Executive functions Planning, multitasking, and focused
concentration
2 - - 2 2
Functioning and dependency Activities of daily living (ADLs) Competent and independent ability to
complete instrumental (cookingmeals,
housekeeping, managing finances) and
basic (using the toilet, eating meals,
dressing, self-hygiene) ADLs
3 7 2 10 7
Driving Legal implications and issues
surrounding surrendering the patient’s
license
1 1 1 2 2
Maintaining hobbies Continued ability to partake in preferred
leisure activities and hobbies
3 1 - 3 3
Eating behaviors Appetite or frequency of eating - 2 - 2 3
Patients’ independence and autonomy The ability to function as an autonomous
individual, both physically and
psychologically
7 4 1 10 7
Social engagement Socialization and social support 2 1 - 3 3
Physical health and mobility Physical health, fitness, and mobility 2 1 - 3 3
Behavioral and neuropsychiatric Mental health Changes in affect and irritation,
symptoms of anxiety, depression, and
reality distortion
3 5 1 10 6
Maintaining identity or personality Personality traits, knowledge, or
emotional bonds with others
4 4 1 9 7
Challenging and distressing behaviors Verbal or physical aggression, anger, and
injurious behaviors
- 5 1 6 4
Apathy General engagement with their
environment and an interest,
motivation, or enthusiasm for
everyday life
1 3 - 3 1
Sleep patterns Patterns or the duration and frequency of
sleep
- 2 1 3 2
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1
Self-efficacy Patients’ belief and confidence in their
abilities
- 1 - 1 1
Patient length and the quality of life Patient quality of life Living with dignity, leading a fulfilling
life, and an overall sense of satisfaction
with life
2 3 1 6 7
Length of patient life Longevity and staying healthy for as long
as possible
1 - - 1 1
Caregiver-oriented outcomes Caregiver burden The burden associated with care,
including a loss of social life, time
spent caring, stress, mental and
physical impact, and giving up work or
study
1 8 1 9 8
Family participation in care Family members drifting apart since
diagnosis of the illness, an unequal
share of caregiving duties, and the
importance/positives of involving
family in the caregiving process
- 5 2 6 8
Caregiver social support Need for social support as a caregiver, the
reported benefits of providing support
to fellow caregivers via shared
understanding, barriers to seeking
social support, the importance of
seeking social support from family
members, and information regarding
the support services that caregivers use
- 5 1 6 8
Spouses’ “duty” to care Belief that it is the “duty” of the spousal
caregiver to provide care to their ill
partner because of the marital bond
1 2 1 3 2
Quality of patient/caregiver relationship Strain placed on marital and parental
relationships
2 2 - 4 3
Caregiver quality of life Changes to lifestyle, freedom, physical
burden, and emotional impact that
affect life as a whole
- 2 - 2 6
Health, social care, and treatment-
related outcomes
Health services and disease information Disease information provided at various
health services, availability and
relevance of provided information,
quality of communication between
health-care professionals, patients, and
caregivers
5 8 2 11 10
Stability of symptoms and general
symptom control
Treatment expectations or controlling
symptoms at a level that enables
functionality
1 4 1 5 7
Delaying entry into institutional care Stay in their own home for as long as
possible
1 1 2 4 3
Medication side effects The importance of limiting the side
effects
1 2 - 2 6
Certainty of diagnosis Accuracy of diagnosis 2 1 - 2 2
(Continued )
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724importance of outcomes from stakeholder perspectives
[12,14–23,25,27,28,30–35,37,39,41–45].
Only three of the 34 included studies provided any evi-
dence on stakeholders’ views about criteria for a meaningful
delay in disease progression [12,39,41]. Evidence was
sought on either the duration of such a delay or the
symptoms delayed in their onset or worsening, which
would be considered meaningful. These studies gathered
data via stakeholder interviews and clinical assessments of
cognition.6
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7793.2. Outcomes of AD across the spectrum
Table 2 lists 32 outcomes across seven domains which
emerged from the included studies, indicating which stake-
holder(s) considered them important, the number of studies
in which the outcome was described by each stakeholder
group, and the number of countries from which participants
were recruited. Fig. 3 shows the overlap by the stakeholder
group.
The Qmost consistent evidence across the stakeholder
groups is summarized in the following section, including
illustrative quotations and other relevant findings.
3.2.1. Outcomes raised by all stakeholder groups
Eight outcomes, spanning all seven overarching domains,
were considered important by all stakeholder groups. They
emerged from between six and eleven studies, from a range
of evidence types (Table 2).
The impact and importance of memory decline was
considered in relation toMCI and AD. This encompassed re-
calling names and dates and a general sense of forgetfulness.
“.it gets. frustrating to not be able to finish a conversa-
tion without at least having one instance where I don’t
remember a certain item, a name or place” (patient with
MCI) [23]. “I was losing my mother—she was forgetting
people, how to do the most basic things. forgetting who
she was” (familial caregiver of AD patient) [22]. The ten
studies [12,14,16,20–23,33,38,40] reporting this were
conducted in North and South America and Europe.
ADLs and loss of functioning included completion of
routine activities, such as independently managing cooking,
finances, and self-hygiene. Evidence for significance in rela-
tion to MCI and AD came from ten studies
[12,13,16,17,21,24,30,32,38,40] conducted in North and
South America, Europe, and Asia. “Improve ADLs so far
as you know... buttoning up a shirt or closing a zipper”
(physician regarding expectations of treatment) [12]. “A
big issue is car driving.. we have to fight that they give
up.. call the police” (professional describing main topics
emerging after early AD diagnosis) [16].
The importance of maintaining patient independency and
autonomy was discussed in relation to MCI and AD in ten
studies [14,16,18,21,25,27,31–33,35] from North America,
Europe, and Asia. This concept went beyond functional
capacity to the ability to self-govern, preserving both9 January 2019  11:35 pm  ce
Fig. 1. PRISMA flowchart showing citation numbers in each stage of the screening process. Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive
impairment. Q12
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887physical and psychological autonomy. “The issue is [they]
want to maintain [their] autonomy. [They] don’t want to
be patronised” (health-care professional for AD patients)
[16].Fig. 2. Map showing the number of studies recruiting participants from countries
country and so are enumerated on the map more than once; see Table 3). Darker
the scale beneath the map.
FLA 5.5.0 DTD  DADM307_proof The impact of mental health issues, such as anxiety,
depression, and reality distortion, was mentioned in relation
to MCI and AD, with evidence from ten studies
[13,14,16,18,20,27,32,35,38,40] conducted in North andaround the world (some studies included participants from more than one
shading implies a larger number of studies within a country, as shown on
9 January 2019  11:35 pm  ce
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
Table 3
Summary of characteristics and results of included studies
First author; location (language)
(reference)
Participant numbers according to
stakeholder type and AD/MCI patient
status
Methods of data collection and
analysis
Findings
Research question 1: reported
outcomes
Research question 2: definition of a
meaningful delay
Andersen; Canada (English) [12] Mild AD patients: n 5 4
AD caregivers: n 5 4
AD HPs: n 5 11 (nurses, physicians,
pharmacists)
Qualitative: semistructured interviews,
30-60 minutes, thematic analysis
AD patients: memory, general
cognitive health
AD caregivers: stability of symptoms
and general symptom control
AD HPs: stability of symptoms and
general symptom control, delaying
entry into care, patient social
engagement, patient QoL, ADL,
apathy
AD patients: positive results
Q13
of
treatment indicated by slowed rate
of memory loss or improvement in
cognitive function
AD caregivers: positive results
indicated by stabilized symptom/
halting of deterioration
AD HPs: positive results indicated by
stabilization of symptoms to defer
requirement to leave home,
retention of ability to be socially
engaged, improvement in cognitive
or physical function
Barrios; USA (English) [13] MCI patients: n 5 16
MCI caregivers: n 5 33 (study 1),
n 5 16 (study 2)
Quantitative: ranking of 12 outcomes
from 1 (most important) to 12 (least
important)
MCI patients: before the intervention,
MCI patients ranked patient
depression as significantly less
important (mean rank 7.9) than the
MCI caregivers (mean rank 4.2;
P , .01)
MCI caregivers: ADL, patient self-
efficacy, patient mental health,
caregiver QoL, patient QoL; Note:
caregiver burden and caregiver
depression were ranked as the
outcomes with the least priority by
the caregivers.
Beard; USA (English) [14] MCI/mild AD patients: n 5 17
MCI/AD caregivers: n 5 68
Qualitative: 14 focus groups conducted
throughout the USA using a
common interview guide, grounded
theory
MCI/AD patients: patients’ mental
health, independence and
autonomy, social engagement,
physical health and mobility,
judgment, and insight
MCI/AD caregivers: patient
independence and autonomy,
memory
Blieszner; USA (English) [15] MCI caregivers: n 5 86 Mixed methods: individual, face-to-
face interviews, thematic analysis
MCI caregivers: patients’ apathy,
patients’ sleep patterns, caregiver
burden, quality of patient-caregiver
relationship, family participation in
care, health services, and disease
information
Bronner; Germany (English) [16] Mild AD patients: n 5 5
AD caregivers: n 5 6
AD HPs: n 5 13 (physicians, social
Qualitative: individual, face-to-face
semistructured interviews,
categorical content analysis
AD patients: patient independence and
autonomy, spouses’ “duty” to care,
health services, and disease
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engagement workers, legal
guardians, nurses, paid caregiver)
information
AD caregivers: memory, family
participation in care
AD HPs: ADL, patients’ independence
and autonomy, driving, patients’
mental health, maintaining identity
or personality, spouses’ “duty” to
care, caregiver burden, health
services and disease information,
caregiver social support, delaying
entry into care
Cheng; China (English) [17] AD caregivers: n 5 57 (for patients
with mild to moderate AD)
Qualitative: tape recorded diaries,
thematic analysis
AD caregivers: ADL, eating behaviors,
stigma, spouses’ “duty” to care,
caregiver social support, access to
health services and disease
information, patient QoL, caregiver
burden
Dai; China (English) [18] MCI caregivers: n 5 13 Qualitative: individual, in-depth
interviews, grounded theory
MCI caregivers: general cognitive
health, patient independence and
autonomy, patient mental health,
stigma, health services, and disease
information
Dean; UK (English)
(a) [19]
(b) [20]
MCI patients: n 5 23
Study (b) added MCI caregivers:
n 5 20
Qualitative: individual, in-depth
semistructured interviews, thematic
analysis
MCI patients: memory, language and
communication, maintaining
hobbies, patient social engagement,
patients’ mental health, maintaining
identity or personality, caregiver
social support, stigma, certainty of
diagnosis, access to health services
and disease information; (b) MCI
caregivers: health services and
disease information, stigma,
caregiver social support
Frank; UK, US, Spain (English) [21] Mild to moderate AD patients: n 5 18
AD caregivers: n 5 46
Qualitative: focus groups with
caregivers and patients, thematic
analysis
AD patients: ADL, patient
independence, and autonomy
AD caregivers: memory, caregiver
social support
Gelman; USA (English) [22] AD caregivers: n 5 10 Qualitative: counseling sessions were
conducted, categorical content
analysis
AD caregivers: memory, patient sleep
patterns, spouses’ “duty” to care,
caregiver burden, family
participation in care, health
services, and disease information
Gordon; USA (English) [23] MCI patients: n 5 25 Qualitative: mixture of focus groups
and individual meetings, thematic
analysis
MCI patients: memory, language and
communication, executive
functions
Hauber; USA and Germany (English)
[24]
AD caregivers: n 5 400 (USA) and
403 (Germany)
Quantitative: 15 best-worst scaling
questions that correspond to 10
activities from the Disability
Assessment for Dementia
AD caregivers: ADL, eating behaviors
(Continued )
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Table 3
Summary of characteristics and results of included studies (Continued )
First author; location (language)
(reference)
Participant numbers according to
stakeholder type and AD/MCI patient
status
Methods of data collection and
analysis
Findings
Research question 1: reported
outcomes
Research question 2: definition of a
meaningful delay
Hulko; Canada (English) [25] Mild to severe AD patients: n5 4 (not
possible to differentiate by AD
stage)
Qualitative: participant observation
sessions, in-home interviews, and
focus groups, grounded theory
AD patients: patients’ independence
and autonomy, quality of patient-
caregiver relationship, health
services, and disease information
Jones; France, Germany, Italy, Spain,
UK (English) [26]
AD caregivers: n5 250 (50 from each
location)
AD HPs: n 5 500 (100 from each
location), half specialists (e.g.,
neurologist/neuropsychiatrist) and
half generalists.
Quantitative: surveys consisting of a
series of attitudinal statements
requiring a response on a Likert
scale
AD caregivers: caregiver burden,
caregiver QoL, family participation
in care
AD HPs: caregiver QoL, health
services and disease information,
family participation in care
Joosten-Weyn; Netherlands (English)
[27]
MCI patients: n 5 8 Qualitative: individual interviews,
grounded theory
MCI patients: executive functions,
physical health and mobility, patient
independence and autonomy,
patient mental health, maintaining
identity or personality
Kunneman; Netherlands (English) [28] MCI patients: n 5 1; mild AD: n 5 2;
AD: n 5 3
MCI/AD caregivers: n 5 6
Mixed methods: focus groups, content
analysis
MCI/AD patients: certainty of
diagnosis, health services, and
disease information
MCI/AD caregivers: certainty of
diagnosis
Kurz; Brazil, Canada, France,
Germany, Spain, USA (English)
[29]
Mild to moderate AD patients: n5 502
(w100 from each of USA, France,
Germany, Spain, Brazil)
AD caregivers: n 5 614 (as above,
w100 from Canada)
Quantitative: survey AD patients: stability of symptoms and
general symptom control,
medication side effects, health
services and disease information,
patient QoL
AD caregivers: caregiver social
support, medication side effects,
health services, and disease
information
Lenardt; Brazil (Portuguese) [30] AD caregivers: n 5 14 (patients with
mild to moderate AD)
Qualitative: semistructured interviews,
taxonomic analysis
AD caregivers: ADL, challenging and
distressing behaviors, caregiver
burden, maintaining identity or
personality
Lu; USA (English) [31] MCI caregivers: n 5 10 Qualitative: open-ended interviews,
interpretive phenomenological
analysis
MCI caregivers: language and
communication, patient
independence and autonomy,
challenging and distressing
behaviors, maintaining identity or
personality, caregiver burden,
quality of patient/caregiver
relationship
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Lu; USA (English) [32] MCI patients: n 5 9 (7 male)
MCI caregivers: n 5 9
Qualitative: focus groups, content
analysis
MCI patients: ADL, patients’
independence and autonomy
MCI caregivers: language and
communication, ADL, patients’
mental health
MacRae; Canada (English)
(a) [33]
(b) [34]
Mild AD patients: n5 8, (b) added one
further patient with AD (total n5 9)
Qualitative: in-depth, semistructured
interviews, thematic analysis
AD patients: memory, patient
independence and autonomy,
delaying entry into care,
maintaining identity or personality,
stigma, length of patient life, patient
QoL, length of patient life
Malthouse; UK (English) [35] Mild AD patients: n 5 5
AD caregivers: n 5 5
Qualitative: open-ended interviews,
thematic analysis
AD patients: patients’ independence
and autonomy
AD caregivers: physical health and
mobility, patients’ mental health
Naumann; Germany (German) [36] AD caregivers: n 5 35 Quantitative: 25 outcomes (referred to
as ‘benefit aspects’) were ranked for
priority. Average scores for each
item were calculated.
AD caregivers: language and
communication, delaying entry into
care, challenging and distressing
behaviors, stability of symptoms
and general symptom control,
patient QoL
Oremus; Canada (English) [37] AD caregivers: n 5 216 (patients with
mild (81%) or moderate (19%) AD
Quantitative: questionnaire, regression
analysis
AD caregivers: medication side effects
Pavarini; Brazil (Portuguese) [38] AD caregivers: n 5 14 (patients with
probable, mild AD)
Qualitative: interviews, categorical
content analysis
AD caregivers: memory, ADL,
caregiver burden, health services
and disease information, patients’
social engagement, patients’ mental
health, patients’ challenging and
distressing behaviors, family
participation in care
Rockwood; Canada (English) [39] AD HPs: number and specialty not
stated
Mild to moderate AD patients: n 5 99
AD caregivers: n 5 99
Quantitative: clinical assessment using
ADAS-Cog at 8-week intervals over
24 weeks compared to changes on
other assessments (PGAS, CGAS,
CIBIC+) measured by clinician
interview
At group-level analysis, a 4-point
improvement was significantly
related to improvements on other
assessments. Worsening scores
were nonsignificantly related to
clinical changes. At individual
level, there was substantial
variability, with around half
misclassified; often when ADAS-
Cog detected no change, clinically
meaningful effects could be
detected.
Ropacki; USA (English) [40] MCI patients: n 5 25
MCI caregivers: n 5 25
Quantitative: focus groups, categorical
content analysis
MCI patients: memory, language and
communication, judgment and
insight, ADL, maintaining hobbies,
driving, patient apathy, patient sleep
patterns, patient mental health,
caregiver burden, maintaining
identity and personality
(Continued )
F
L
A
5
.5
.0
D
T
D

D
A
D
M
30
7
_
p
ro
o
f

9
Ja
n
u
a
ry
2
0
1
9

1
1
:3
5
p
m

ce
C
.
To
ch
el
et
a
l.
/
A
lzh
eim
er’s
&
D
em
en
tia
:
D
ia
g
n
o
sis,
A
ssessm
en
t
&
D
isea
se
M
o
n
ito
ring
-
(2
0
1
8
)
1
-1
7
1
1
1
3
1
6
1
3
1
7
1
3
1
8
1
3
1
9
1
3
2
0
1
3
2
1
1
3
2
2
1
3
2
3
1
3
2
4
1
3
2
5
1
3
2
6
1
3
2
7
1
3
2
8
1
3
2
9
1
3
3
0
1
3
3
1
1
3
3
2
1
3
3
3
1
3
3
4
1
3
3
5
1
3
3
6
1
3
3
7
1
3
3
8
1
3
3
9
1
3
4
0
1
3
4
1
1
3
4
2
1
3
4
3
1
3
4
4
1
3
4
5
1
3
4
6
1
3
4
7
1
3
4
8
1
3
4
9
1
3
5
0
1
3
5
1
1
3
5
2
1
3
5
3
1
3
5
4
1
3
5
5
1
3
5
6
1
3
5
7
1
3
5
8
1
3
5
9
1
3
6
0
1
3
6
1
1
3
6
2
1
3
6
3
1
3
6
4
1
3
6
5
1
3
6
6
1
3
6
7
1
3
6
8
1
3
6
9
1
3
7
0
1
3
7
1
1
3
7
2
1
3
7
3
1
3
7
4
1
3
7
5
1
3
7
6
1
3
7
7
1
3
7
8
1
3
7
9
1
3
8
0
1
3
8
1
1
3
8
2
1
3
8
3
1
3
8
4
1
3
8
5
1
3
8
6
1
3
8
7
1
3
8
8
1
3
8
9
1
3
9
0
1
3
9
1
1
3
9
2
1
3
9
3
1
3
9
4
1
3
9
5
1
3
9
6
1
3
9
7
1
3
9
8
1
3
9
9
1
4
0
0
1
4
0
1
1
4
0
2
1
4
0
3
1
4
0
4
1
4
0
5
1
4
0
6
1
4
0
7
1
4
0
8
1
4
0
9
1
4
1
0
1
4
1
1
1
4
1
2
1
4
1
3
1
4
1
4
1
4
1
5
1
4
1
6
1
4
1
7
1
4
1
8
1
4
1
9
1
4
2
0
1
4
2
1
1
4
2
2
1
4
2
3
1
4
2
4
1
4
2
5
1
4
2
6
1
4
2
7
1
4
2
8
1
4
2
9
1
4
3
0
1
4
3
1
1
4
3
2
1
4
3
3
1
4
3
4
1
4
3
5
1
4
3
6
1
4
3
7
1
4
3
8
1
4
3
9
1
4
4
0
1
4
4
1
1
4
4
2
1
4
4
3
1
4
4
4
1
4
4
5
1
4
4
6
1
4
4
7
1
4
4
8
1
4
4
9
Table 3
Summary of characteristics and results of included studies (Continued )
First author; location (language)
(reference)
Participant numbers according to
stakeholder type and AD/MCI patient
status
Methods of data collection and
analysis
Findings
Research question 1: reported
outcomes
Research question 2: definition of a
meaningful delay
MCI caregivers: memory, judgment
and insight, ADL, maintaining
hobbies, driving, patient apathy,
patient sleep patterns, challenging
and distressing behaviors,
maintaining identity or personality,
caregiver burden
Schrag; UK (English) [41] Mild AD patients: n 5 181
AD HPs: number and specialty not
stated, all based within
neuroimaging initiative sites
Quantitative: ADAS-Cog compared to
clinician-assessed memory and
nonmemory cognitive function
using FAQ and CDRS
ADAS-Cog scores among those with a
clinically relevant change at
6 months were between 3.1 and 3.8.
Scores in those without a clinical
change were between 1.9 and 2.0.
Minimally, clinically relevant
changes determined to be 3 points.
Smith; Australia (English) [42] AD patients: n 5 5
AD caregivers: n 5 6
Qualitative: in-depth, semistructured
interviews, thematic analysis
AD patients: stability of symptoms and
general symptom control
Smith; Canada (English) [43] AD caregivers: n 5 17 (16 patients
with early to moderate AD, 1 with
moderate to severe AD)
Qualitative: in-depth narrative
interviews conducted, grounded
theory
AD caregivers: maintaining identity or
personality, stability of symptoms,
and general symptom control
Sorensen; Denmark (English) [44] Patients with mild AD: n 5 11 Qualitative: semistructured interviews,
grounded theory
AD patients: maintaining hobbies,
maintaining identity or personality,
quality of patient-caregiver
relationship
Yektatalab; Iran (English) [35] AD HPs: n 5 14, clinical and social
caregivers for residents in a nursing
home
Qualitative: interviews with open-
ended questions, descriptive content
analysis
AD HPs: challenging and distressing
behaviors, family participation in
care
Abbreviations: AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; ADL, activities of daily living; CIBIC+, Clinician Interview-Based Impression of Change
plus caregiver input; CGAS, clinician Goal-Attainment Scaling; FAQ, functional activities questionnaire; HPs, health-care professionals; MCI, mild cognitive impairment; PGAS, patient/carer Goal-Attainment
Scaling; QoL, quality of life.
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Fig. 3. Overlap of outcomes according to the stakeholder group which raised their importance and the number of studies in which they appeared. Q15
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1717South America, Europe, and Asia. When asked which key
areas should be targeted in an intervention for MCI,
spousal caregivers believed that targeting depression was
important [32].
The importance of maintaining patient quality of life
(QoL) (encompassing the concepts of living a fulfilled and
dignified life) was highlighted in relation to MCI and AD;
evidence came from six studies [12,13,17,29,33,36]
conducted in North and South America, Europe, and Asia.
In one study, caregivers of patients with MCI ranked
patient QoL as the most important outcome from a
predetermined list of twelve outcomes [13].
Maintenance of patients’ identity and personality was
discussed in relation to MCI and AD in nine studies
[16,20,27,30,31,33,40,43,44] carried out in North and
South America and Europe. This related to the
preservation of personality traits, knowledge, and
emotional bonds with others. “My best friend [husband
with MCI] has gone. He is part of me, but he is no longer
the same person. I really miss him” [31].
The impact of the disease through caregiver burden was
discussed in relation to MCI and AD in nine studies [15–
17,22,26,30,31,38,40] carried out in North and South
America, Europe, and Asia. “I quit my job, my house, to
take care of her. I do not go to the cinema, I do not go out
for a walk, I do not go to the shopping mall, I do not go to
the hairdresser” (caregiver of AD patient) [30].FLA 5.5.0 DTD  DADM307_proof The importance of health services and disease informa-
tion (and its absence) was discussed by all stakeholder
groups in relation to MCI and AD in eleven studies [15–
19,22,25,26,28,29,38] from North and South America,
Europe, and Asia. “If there is something I don’t
understand, I will go on [the computer] and look it up. I
just want to be able, [if] something happens, [to] take care
of him as far as [possible] in every situation.” (caregiver
of an AD patient) [15].
3.2.2. Outcomes raised by both patients and caregivers
Patients and caregivers mentioned the importance of re-
taining language and communication functions in relation
to MCI and AD. This included cognitive aspects of verbal
and written communication, such as verbal fluency and ob-
ject naming. Evidence came from six studies
[20,23,31,32,36,40] conducted in North America and
Europe, including one study in which familial caregivers
of AD patients ranked “improvement to communication
abilities” as the fourth most important of a predetermined
list of 25 outcomes [36].
Patients and caregivers dealing with MCI and AD dis-
cussed the importance of maintaining a quality patient-care-
giver relationship. Evidence emerged from four studies
[15,25,31,44] conducted in North America, Europe, and
Asia. “My husband gets angry with me when I can’t
remember things we have decided to do. He talks a lot9 January 2019  11:35 pm  ce
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1837about it. Sometimes I think that it is worse for him than for
me” (a patient with AD) [44].
The impact of experiencing stigma due to AD emerged in
four studies [17,18,20,33] conducted in North America,
Europe, and Asia. Stakeholders described anticipated,
perceived, and overt stereotyping because of AD. “We
haven’t discussed this, but I get the feeling that [my
husband] wouldn’t like that, because there is a certain
amount of stigma attached to dementia. So no, I haven’t”
(wife of an AD patient when asked about seeking social
support) [20].
3.2.3. Outcomes mentioned by both health-care
professionals and caregivers
Both health-care professionals and caregivers discussed
the difficulty of dealing with challenging and distressing be-
haviors in relation toMCI and AD, such as verbal or physical
aggression. Evidence came from six studies
[30,31,36,38,40,45] conducted in North and South
America, Europe, and Asia. “If you don’t have patience
here, you won’t last for even 2 months because of patients’
yelling and their aggression” (a paid caregiver of AD
patients) [45].
The benefits of caregiver social support and the chal-
lenges of accessing it were discussed in relation to MCI
and AD, with evidence from six studies [16,17,19–21,29]
from North and South America, Europe, and Asia. “I
started to realize that I should get someone to talk to when
feeling helpless sometimes. I felt better after letting
everything out from within” (a caregiver of AD patients)
[17].
Patients dealing with MCI and AD described the impor-
tance of maintaining family participation in care throughout
the disease process to preserve relationships and spread
duties. This emerged in six studies [15,16,22,26,38,45]
conducted in North and South America, Europe, and Asia.
“He (the patient) loved his sister so much, and now she
won’t even call to see how he’s doing. She’s angry that I
keep insisting there’s something wrong, and that he ‘took
my side’ because he hasn’t called her. But of course he
can’t call her. This is tearing the family apart.” (a
caregiver of an AD patient) [22].
Outcomes discussed less frequently are described in
Table 2 and Fig. 3.1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
18513.3. Meaningful delay
Only three included studies [12,39,41] reported relevant
statements or data relating to changes in outcomes of the
disease over time, and none comprehensively defined what
constituted a meaningful delay in disease progression from
stakeholders’ perspectives. One study involving patients
with mild AD described changes in symptomatology
without specific reference to time periods (e.g., slowing
memory deterioration and retaining ability to undertake
ADLs) [12] (details are shown in Table 3). Two studiesFLA 5.5.0 DTD  DADM307_proof involving patients with mild to moderate AD referred to dis-
ease progression in terms of cutoff points on the ADAssess-
ment Scale-Cognitive describing 3- [41] or 4-point changes
[39] as clinically meaningful. Authors of both these studies
emphasized that although these changes may be significant
when analyzed at a group level, there was a substantial vari-
ation among individuals and their experienced symptoms at
any given score on the scale.4. Discussion
Our systematic review provides a framework of real-
world outcomes which represents the voices of stakeholders
personally impacted by AD across the spectrum of disease,
adding a different perspective to the previous work based
on AD trial outcomes and their measures [46,47].
Important outcomes included clinical aspects of the
disease, e.g., memory and mental health, and social
aspects, such as the devastating impact of caregiver
burden. Other frequently observed important outcomes
reflect practical challenges such as accessing AD
information or the ability to complete ADLs alongside
personal aspects such as maintenance of patient autonomy,
identity, and QoL.
Our review identified the importance of several outcomes
consistent with those typically assessed in clinical trials,
such as cognition and ADLs. However, we revealed the
importance of several additional outcomes that are infre-
quently assessed in clinical trial settings, including preserva-
tion of the patient’s personality or the accessibility of health
services and disease information. These concepts may be
captured by patient reported outcome and experience mea-
sures [48], which can be used to describe and evaluate the
effectiveness of treatments and quality of care, respectively,
and their use may enhance patient and carer engagement
with—and so recruitment to—clinical trials.
Stakeholders prioritized outcomes with tangible and
directly observable effects on the daily lives of patients
and caregivers. Disease biomarkers (e.g., those based on
tau or amyloid, structural neuroimaging measures, or combi-
nation of these) are now incorporated into research diag-
nostic criteria and therefore commonly used to assess
interventions in clinical trials [2]. These were not mentioned
by stakeholders, although the desire for certainty of diag-
nosis was identified in two studies. It is possible that clinical
biomarker-based outcomes were not flagged as being impor-
tant because of the sparsity of data from health-care profes-
sionals (six of the 34 included studies), the lack of data from
people with prodromal or severe AD, and/or the relatively
new and tentative nature of the evidence linking biomarkers
to clinical symptomatology.
Although we identified a substantial body of research re-
porting on the importance of various outcomes to stake-
holders, no reliable conclusions relating to the definition of
a meaningful delay in AD progression could be drawn.
The available evidence highlighted the difficulty of using9 January 2019  11:35 pm  ce
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1914
1915
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1918
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1920
1921
1922
1923scales to determine clinically relevant or meaningful change
because these are not accurate or predictive of symptoms at
the individual level, suggesting the need for further investi-
gation of this issue.7
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1957
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1959
19604.1. Strengths and limitations
This review benefitted from the multidisciplinary team of
researchers and experts across Europe who conducted the
work and contributed at key decision-making stages.
The inclusion of studies published in multiple languages
in different countries (although few from developing coun-
tries) improves the generalizability of the evidence, and its
methodological heterogeneity adds confidence by incorpo-
rating outcomes that emerged from a range of study types.
This combined evidence facilitates a complete understand-
ing of stakeholder perspectives.
Although our search strategy was relatively sensitive, it
may not have captured all relevant material. We used the
term “patient” with condition terms to identify individuals
with AD across the spectrum, so relevant studies may have
been missed which used terms such as “person” or “subject”.
We found no studies that addressed the opinions of patients
or corresponding stakeholders at the severe end of the AD
spectrum. Given the time-intensive and complex nature of
qualitative work and the requirement of appropriate consent
procedures, it would be practically and ethically difficult to
conduct such research. We also did not capture the opinions
of former caregivers of people with AD. Both groups repre-
sent important missing voices in the evidence presented. The
interpretation of research evidence into outcomes and their
categorization into domains may have obscured some rele-
vant concepts. For example, language and communication
may have been captured by the broader “cognition” domain
from the perspective of health-care professionals.8
9
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
19855. Conclusions
Our systematic review provides evidence about the out-
comes of MCI and mild to moderate AD dementia which
are of importance to patients, caregivers, and health-care
professionals. It demonstrates that although current clinical
trials typically assess some of these, others are rarely
included as outcomes. Involving these varied and nuanced
AD outcomes in the trial design would be a substantial chal-
lenge, but as they reflect distinct, important aspects of the
experience and burden of the disease, they could help ensure
that successful treatments or evaluation of the quality of care
is better focused on aspects of ADmost important to the peo-
ple affected by it.
As there was limited evidence to define a “meaningful
delay in AD disease progression” from any of the stake-
holders’ perspectives, further research is essential to explore
this important issue at different stages of the AD spectrum.
AD outcomes of importance in preclinical and severe stages
of the disease should also be explored.FLA 5.5.0 DTD  DADM307_proof Our findings will help future researchers meet the chal-
lenge of designing and undertaking optimized clinical trials
with the greatest potential to provide treatments for AD
which mitigate its most devastating effects at a personal
and social level.
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1. Systematic review: The authors searched four data-
bases (Medline, Embase, CINAHL, and PsycINFO)
and online sources of gray literature for research pub-
lished in any language which elicited the views of
stakeholders to identify clinical and nonclinical out-
comes of Alzheimer’s disease which were important
to them.
2. Interpretation: There was consistent evidence across
stakeholder groups, countries where studies were
based, and study methodologies. Overall, 32 out-
comes encompassed by seven broad domains were
uncovered, reflecting impacts across the spectrum
of the disease. There was more evidence for the
importance of patient memory, activities of daily
living, quality of life, independence and autonomy,
mental health, maintaining identity and personality,
caregiver burden, and access to health services and
disease information.
3. Future directions: Understanding which real-world
outcomes of Alzheimer’s disease are most relevant
to patients, caregivers, and health-care professionals
should help guide future research to develop relevant,
effective treatments and improve health services.References Q
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